Financing ·
On August 27, 2026, BioLineRx Ltd. entered into a securities purchase agreement for a registered direct offering of…
BLRXBioLineRx Ltd.
On August 27, 2026, BioLineRx Ltd. entered into a securities purchase agreement for a registered direct offering of 480,696 American Depositary Shares (ADSs) and pre-funded warrants to purchase up to 868,225 ADSs, along with unregistered warrants for up to 2,023,382 ADSs. The aggregate gross proceeds are expected to be approximately $3,750,000 before fees. Chardan Capital Markets LLC serves as the exclusive placement agent. Concurrently, BioLineRx amended existing warrants held by the purchaser to reduce the exercise price to $2.78 per ADS and extend the term until August 31, 2031. The offering is expected to close on or about August 31, 2026, with net proceeds intended for research and development and working capital. BioLineRx Ltd. operates in the biotechnology industry, focusing on the discovery and development of cancer therapies.